Home › Companies › CRBU
Pipeline (0 active programs)
No active programs disclosed.
Technology platforms
Discontinued (6)
- vispacabtagene regedleucel — Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma · plans to discontinue further development activities for its two allogeneic CAR-T cell therapy programs (vispa-cel, CB-011) while evaluating strategic alternatives
- CB-011 — Relapsed/Refractory Multiple Myeloma · strategic deprioritization; financing environment for allogeneic CAR-T therapies
- vispacabtagene regedleucel — Lupus · discontinued GALLOP phase 1 trial prior to dosing the first patient as part of strategic pipeline prioritization
- CB-012 — Relapsed/Refractory Acute Myeloid Leukemia · discontinued AMpLify phase 1 clinical trial as additional data would be needed to advance this program; license agreement with MSKCC terminated
- vispacabtagene regedleucel — Relapsed/Refractory Large B Cell Lymphoma · plans to discontinue further development activities for its two allogeneic CAR-T cell therapy programs (vispa-cel, CB-011) while evaluating strategic alternatives
- vispacabtagene regedleucel — Large B-Cell Lymphoma · plans to discontinue further development activities for its two allogeneic CAR-T cell therapy programs (vispa-cel, CB-011) while evaluating strategic alternatives
Biotech Distilled coverage (5)
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
